Unveiling the Top 5 Who Manufactures Eliquis Suppliers for Your Bus…

Introduction: Navigating the Global Market for who manufactures eliquis

In the complex landscape of pharmaceuticals, sourcing reliable information about who manufactures ELIQUIS (apixaban) can pose a significant challenge for international B2B buyers. With the growing demand for effective anticoagulants in markets across Africa, South America, the Middle East, and Europe, understanding the manufacturing landscape is crucial for making informed purchasing decisions. This guide serves as a comprehensive resource, detailing the key manufacturers of ELIQUIS, their production capabilities, and the regulatory frameworks governing their operations.

Within this guide, you will find an in-depth analysis of the various types of manufacturers, including major pharmaceutical companies like Bristol Myers Squibb and Pfizer, and their roles in the global market. Additionally, we will explore the applications of ELIQUIS in treating conditions such as nonvalvular atrial fibrillation and deep vein thrombosis, alongside insights into the supplier vetting process, cost considerations, and quality assurance measures.

By equipping B2B buyers with actionable insights and practical strategies, this guide empowers stakeholders to navigate the intricate supply chain of ELIQUIS. Whether you are looking to establish new supplier relationships or streamline your procurement process, understanding who manufactures ELIQUIS will enhance your ability to secure quality products that meet regulatory standards and patient needs.

Top 10 Who Manufactures Eliquis Manufacturers & Suppliers List

Understanding who manufactures eliquis Types and Variations

Type Name	Key Distinguishing Features	Primary B2B Applications	Brief Pros & Cons for Buyers
Original Brand Manufacturer	Developed and marketed by Bristol Myers Squibb (BMS) and Pfizer.	Hospitals, pharmacies, and healthcare systems.	Pros: High quality, trusted brand. Cons: Higher cost compared to generics.
Generic Manufacturers	Companies producing apixaban under different brand names.	Cost-sensitive healthcare providers.	Pros: Lower cost, wider accessibility. Cons: Potential variability in quality.
Contract Manufacturers	Third-party manufacturers producing ELIQUIS for other brands.	Pharmaceutical companies looking to outsource.	Pros: Flexibility in production, can scale quickly. Cons: Less control over quality standards.
Specialty Pharmacies	Focus on unique formulations or patient-specific needs.	Niche markets, patients with specific conditions.	Pros: Tailored solutions, personalized service. Cons: Limited availability and higher prices.
International Suppliers	Global manufacturers catering to specific regions like Africa or South America.	Emerging markets, local pharmacies.	Pros: Localized supply chains, competitive pricing. Cons: Regulatory challenges, potential quality concerns.

What are the Key Characteristics of the Original Brand Manufacturer of ELIQUIS?

The original brand manufacturers, primarily Bristol Myers Squibb and Pfizer, are responsible for the development and marketing of ELIQUIS. Their reputation for quality and adherence to regulatory standards makes them a preferred choice for hospitals and healthcare systems. When purchasing from these manufacturers, B2B buyers can expect comprehensive patient support programs and reliable supply chains. However, the higher costs associated with these branded products may be a concern for budget-conscious buyers.

How Do Generic Manufacturers of ELIQUIS Differ from Original Brands?

Generic manufacturers produce apixaban under various brand names, offering a more cost-effective alternative to the original ELIQUIS. These products are essential for healthcare providers operating within tight budget constraints, allowing for broader patient access to necessary medications. While the lower price point is advantageous, buyers must consider potential variability in quality and efficacy compared to the branded version, which could impact patient outcomes.

What is the Role of Contract Manufacturers in ELIQUIS Production?

Contract manufacturers specialize in producing pharmaceuticals for other companies, including ELIQUIS. This arrangement allows pharmaceutical companies to scale production without investing heavily in manufacturing infrastructure. B2B buyers may find this appealing as it can lead to cost savings and increased efficiency. However, the challenge lies in maintaining quality standards and ensuring that the contract manufacturers adhere to the same rigorous guidelines as the original brands.

How Do Specialty Pharmacies Cater to Unique ELIQUIS Needs?

Specialty pharmacies focus on providing personalized care, often formulating unique versions of ELIQUIS tailored to specific patient needs, such as dosage adjustments or delivery methods. These pharmacies are particularly valuable in niche markets where standard formulations may not suffice. While their services enhance patient care, the higher prices and limited availability may deter some buyers from opting for these specialized solutions.

What Are the Advantages of International Suppliers for ELIQUIS?

International suppliers play a crucial role in distributing ELIQUIS to emerging markets, particularly in regions like Africa and South America. They often provide competitive pricing and localized supply chains, making the medication more accessible to healthcare providers in these areas. However, buyers must navigate regulatory challenges and potential concerns regarding product quality and consistency, which can vary significantly between suppliers.

Key Industrial Applications of who manufactures eliquis

Industry/Sector	Specific Application of who manufactures eliquis	Value/Benefit for the Business	Key Sourcing Considerations for this Application
Healthcare	Treatment of non-valvular atrial fibrillation (AFib)	Reduces the risk of stroke, enhancing patient outcomes and satisfaction	Regulatory compliance, supply chain reliability, and cost management
Pharmaceuticals	Co-promotion and distribution partnerships	Expands market reach and improves accessibility for patients	Licensing agreements, distribution channels, and market analysis
Surgical Facilities	Post-operative care for hip and knee replacement surgeries	Minimizes complications from blood clots, improving recovery rates	Inventory management, timely delivery, and patient safety protocols
Insurance Providers	Coverage plans for ELIQUIS	Enhances patient adherence to treatment, leading to better health outcomes	Understanding regional healthcare regulations and reimbursement policies
Research Institutions	Clinical trials for new anticoagulant therapies	Contributes to innovative treatments and advancements in patient care	Ethical approval, funding, and collaboration with healthcare providers

How is ELIQUIS Used in Healthcare Settings?

In healthcare, ELIQUIS is primarily prescribed for patients with non-valvular atrial fibrillation (AFib) to mitigate stroke risk. This application is crucial for hospitals and clinics, particularly in regions like Africa and South America, where stroke prevalence is high. B2B buyers in this sector must consider regulatory compliance and the reliability of supply chains to ensure that ELIQUIS is available when needed.

What Role Does ELIQUIS Play in Pharmaceuticals?

Pharmaceutical companies often seek co-promotion and distribution partnerships with the manufacturers of ELIQUIS. This collaboration can help expand market reach and improve patient access to the medication. For international buyers, understanding licensing agreements and distribution channels is essential to ensure a successful partnership and compliance with local regulations.

Why is ELIQUIS Important in Surgical Facilities?

In surgical facilities, ELIQUIS is utilized for post-operative care, especially after hip and knee replacements. Its role in reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism is vital for improving recovery rates. Buyers must focus on effective inventory management and timely delivery to ensure that patients receive necessary medications promptly, adhering to patient safety protocols.

How Do Insurance Providers Benefit from ELIQUIS?

Insurance providers include ELIQUIS in their coverage plans to enhance patient adherence to anticoagulant therapy. This not only improves health outcomes but also reduces long-term healthcare costs associated with complications from untreated conditions. Buyers in this sector should be well-versed in regional healthcare regulations and reimbursement policies to ensure that ELIQUIS is accessible to patients in various markets.

What is the Significance of ELIQUIS in Research Institutions?

Research institutions utilize ELIQUIS in clinical trials aimed at developing new anticoagulant therapies. This application is essential for advancing medical science and improving treatment options for patients. For B2B buyers in research, considerations such as ethical approvals, funding, and collaboration with healthcare providers are critical to the success of these initiatives.

3 Common User Pain Points for ‘who manufactures eliquis’ & Their Solutions

Scenario 1: Difficulty in Assessing Quality and Compliance of ELIQUIS Manufacturers

The Problem: B2B buyers in the pharmaceutical sector, especially those in regions such as Africa and the Middle East, often struggle with ensuring the quality and compliance of medications sourced from various manufacturers. With ELIQUIS (apixaban) being a critical anticoagulant, concerns about the manufacturing standards, regulatory approvals, and potential counterfeit products can create significant hesitation in procurement decisions. Buyers need assurance that the products they source meet both local and international safety standards.

The Solution: To mitigate these concerns, B2B buyers should establish relationships with reputable suppliers and distributors who have a proven track record in the pharmaceutical industry. Begin by conducting thorough due diligence, which includes verifying the manufacturer’s certifications such as GMP (Good Manufacturing Practices) and FDA approvals, if applicable. Consider requesting samples for quality testing and analysis before committing to bulk purchases. Furthermore, utilizing platforms that aggregate manufacturer ratings and reviews can provide valuable insights into the reliability of ELIQUIS suppliers. Engaging in continuous monitoring and establishing clear communication channels with manufacturers can also help ensure that any issues regarding quality or compliance are addressed promptly.

Scenario 2: Navigating Pricing and Cost Management Challenges

The Problem: International buyers often face challenges in managing costs when procuring ELIQUIS, especially in regions where pricing can fluctuate due to import tariffs, currency exchange rates, and local market conditions. This unpredictability can lead to budget overruns and hinder the ability to provide consistent access to essential medications for patients.

The Solution: To tackle pricing challenges, B2B buyers should negotiate long-term contracts with manufacturers or authorized distributors that include fixed pricing agreements. This strategy can help stabilize costs over time, providing more predictable budgeting for procurement. Additionally, buyers can explore options for bulk purchasing discounts or loyalty programs that some manufacturers offer. Staying informed about regional pricing trends and leveraging group purchasing organizations (GPOs) can also provide negotiation power, resulting in better pricing structures. Finally, implementing a robust inventory management system can help optimize stock levels, reducing the need for rushed purchases that often come with premium pricing.

Scenario 3: Ensuring Timely Delivery and Supply Chain Reliability

The Problem: Timely delivery of ELIQUIS is crucial for healthcare providers, particularly in regions with limited access to critical medications. Delays in shipment can result in stockouts, impacting patient care and leading to frustration among healthcare professionals and patients alike. B2B buyers often find themselves at the mercy of logistics and supply chain issues, which can be exacerbated by geopolitical factors or natural disasters.

The Solution: To enhance supply chain reliability, B2B buyers should establish partnerships with multiple manufacturers and suppliers to create a diversified sourcing strategy. This approach mitigates risks associated with relying on a single supplier. Additionally, buyers can implement advanced supply chain management tools that provide real-time tracking of shipments and inventory levels. Regularly communicating with suppliers about lead times and potential disruptions can also ensure that buyers are prepared for any changes. Building a buffer stock of ELIQUIS can further safeguard against unexpected delays, enabling healthcare providers to maintain consistent patient care. Lastly, engaging in collaborative planning with suppliers can enhance overall supply chain resilience and responsiveness to market demands.

Strategic Material Selection Guide for who manufactures eliquis

What Materials Are Commonly Used in the Manufacture of ELIQUIS?

When considering the manufacturing of ELIQUIS (apixaban), a leading oral anticoagulant, the selection of materials is crucial for ensuring product quality, safety, and efficacy. Below, we analyze several key materials commonly used in the production of pharmaceutical products like ELIQUIS, focusing on their properties, advantages, disadvantages, and considerations for international B2B buyers.

What Are the Key Properties of Active Pharmaceutical Ingredients (APIs) in ELIQUIS?

Active Pharmaceutical Ingredients (APIs), such as apixaban, are the core components that provide therapeutic effects. Key properties include:

• Purity and Potency: APIs must meet stringent purity standards to ensure efficacy and safety.
• Stability: They should maintain stability under various temperature and humidity conditions, typically requiring storage at controlled temperatures.
• Solubility: High solubility in biological fluids is essential for effective absorption.

Pros & Cons: The primary advantage of high-quality APIs is their effectiveness in achieving desired health outcomes. However, sourcing high-purity APIs can be costly and may involve complex regulatory compliance, particularly in international markets.

How Do Excipients Impact the Performance of ELIQUIS?

Excipients are inactive substances that serve as carriers for the active ingredients. Common excipients in ELIQUIS formulations include lactose, microcrystalline cellulose, and magnesium stearate.

• Key Properties: They must be non-reactive, compatible with APIs, and enhance the stability and bioavailability of the drug.
• Pros & Cons: Excipients improve the manufacturability of the drug and patient compliance. However, they can add to the overall cost and may introduce variability in product performance if not carefully selected.

What Role Do Packaging Materials Play in the Safety of ELIQUIS?

Packaging materials are essential for protecting ELIQUIS from environmental factors that could compromise its integrity.

• Key Properties: Materials must be moisture-resistant, tamper-evident, and compatible with the drug formulation.
• Pros & Cons: Effective packaging prolongs shelf life and ensures patient safety. However, high-quality packaging materials can increase production costs and require compliance with various international standards.

How Do Regulatory Considerations Affect Material Selection for ELIQUIS?

International buyers must consider regulatory compliance when selecting materials for ELIQUIS. Different regions have specific standards, such as:

• ASTM (American Society for Testing and Materials): Commonly referenced in the U.S.
• DIN (Deutsches Institut für Normung): Widely used in Europe.
• JIS (Japanese Industrial Standards): Important for Asian markets.

Pros & Cons: Compliance with these standards ensures product safety and efficacy, but navigating the regulatory landscape can be complex and time-consuming, particularly for buyers in emerging markets like Africa and South America.

Summary Table of Material Selection for ELIQUIS

Material	Typical Use Case for who manufactures eliquis	Key Advantage	Key Disadvantage/Limitation	Relative Cost (Low/Med/High)
Active Pharmaceutical Ingredients (APIs)	Core component of ELIQUIS formulation	High efficacy and therapeutic effect	High sourcing costs and regulatory complexity	High
Excipients	Enhance stability and bioavailability	Improve manufacturability and patient compliance	Can introduce variability and increase costs	Medium
Packaging Materials	Protect drug from environmental factors	Prolong shelf life and ensure safety	Increased production costs and compliance issues	Medium
Regulatory Compliance Standards	Ensure safety and efficacy of materials	Builds trust and meets market requirements	Complex navigation for international buyers	High

This strategic material selection guide provides a comprehensive overview for international B2B buyers in the pharmaceutical sector, particularly those sourcing materials for the manufacture of ELIQUIS. Understanding these materials and their implications can lead to better procurement decisions and ultimately enhance product quality and market success.

In-depth Look: Manufacturing Processes and Quality Assurance for who manufactures eliquis

What Are the Key Stages in the Manufacturing Process of ELIQUIS?

The manufacturing of ELIQUIS (apixaban), an oral anticoagulant produced by Bristol Myers Squibb, involves several critical stages to ensure the drug’s efficacy and safety. Understanding these processes can help B2B buyers, particularly those in regions like Africa, South America, the Middle East, and Europe, make informed decisions when sourcing pharmaceutical products.

Material Preparation: How Are Active Ingredients and Excipients Handled?

The first stage of manufacturing involves sourcing high-quality active pharmaceutical ingredients (APIs) and excipients. The APIs for ELIQUIS are synthesized through complex chemical processes that require strict adherence to Good Manufacturing Practices (GMP). Raw materials must undergo rigorous testing for purity and potency before they can enter production.

During this stage, suppliers often perform extensive documentation of material specifications and supplier certifications. B2B buyers should ensure that their suppliers can provide Certificates of Analysis (CoA) for all raw materials, which verify compliance with pharmacopoeial standards.

What Forming Techniques Are Used in ELIQUIS Manufacturing?

Once materials are prepared, the next step is forming the tablets. This typically involves granulation, blending, and compression. Granulation is a crucial process that improves the flowability of powders and ensures uniformity in tablet weight and content.

Common techniques include wet granulation and dry granulation. For ELIQUIS, wet granulation is often preferred as it enhances the dissolution rate of the drug, leading to better bioavailability. Understanding the specific techniques used can help B2B buyers evaluate the potential efficacy of the product they are sourcing.

How Is the Assembly Process Managed for ELIQUIS?

Following the forming stage, the tablets undergo an assembly process, which includes coating and packaging. Coating not only protects the active ingredient but also enhances patient compliance by making the tablets easier to swallow and more visually appealing.

During this phase, manufacturers must ensure that the assembly line is maintained under controlled conditions to prevent contamination. B2B buyers should inquire about the cleanroom standards and environmental controls that suppliers implement during this stage.

What Finishing Touches Are Applied to ELIQUIS Tablets?

The finishing stage involves final inspections and packaging. This is where quality assurance becomes paramount. Tablets are typically subjected to various tests to ensure they meet the required specifications for strength, stability, and release characteristics.

After passing these tests, the final product is packaged in compliance with regulatory requirements. B2B buyers should verify that their suppliers use appropriate packaging materials to protect the drug during transportation and storage, as this can significantly affect the product’s shelf life.

What Quality Control Measures Are Essential for ELIQUIS Manufacturing?

Quality control (QC) is a critical component of the manufacturing process for ELIQUIS. Adhering to international standards and industry-specific guidelines ensures that the product is safe and effective.

Which International Standards Are Relevant for ELIQUIS Quality Assurance?

Manufacturers of ELIQUIS must comply with various international standards, such as ISO 9001 for quality management systems. Additionally, adherence to the European Medicines Agency (EMA) guidelines and the U.S. Food and Drug Administration (FDA) regulations is crucial for market approval in different regions.

For B2B buyers, understanding these standards can help in evaluating the credibility of potential suppliers. It is advisable to request documentation that confirms compliance with these regulations.

What Are the Key Quality Control Checkpoints in ELIQUIS Manufacturing?

Quality control checkpoints are integral to maintaining high standards throughout the manufacturing process. These checkpoints typically include:

• Incoming Quality Control (IQC): This stage involves testing raw materials to ensure they meet predefined specifications before entering production.
• In-Process Quality Control (IPQC): Monitoring occurs during the manufacturing process to ensure that all parameters remain within acceptable limits.
• Final Quality Control (FQC): This is the last line of defense, where the finished product undergoes rigorous testing for potency, purity, and stability.

B2B buyers should inquire about the frequency and methods of these quality checks to ensure that suppliers maintain a high standard of quality assurance.

What Common Testing Methods Are Used in ELIQUIS Quality Control?

Testing methods for ELIQUIS may include High-Performance Liquid Chromatography (HPLC) for potency testing, dissolution testing to assess how quickly the drug is released in the body, and stability testing to determine shelf life.

B2B buyers should consider requesting access to test reports and validation studies from suppliers to verify the robustness of their quality control processes.

How Can B2B Buyers Verify Supplier Quality Control?

Verifying a supplier’s quality control measures is essential for B2B buyers, particularly in the pharmaceutical sector. There are several strategies to ensure that the manufacturers meet the required standards:

What Role Do Audits Play in Supplier Verification?

Conducting audits is one of the most effective ways to assess a supplier’s quality control practices. Buyers should consider performing on-site audits or requesting third-party audit reports to verify compliance with GMP and other relevant standards.

How Can Buyers Access Quality Control Reports?

Suppliers should be willing to provide detailed quality control reports, including results from testing and validation processes. B2B buyers should not hesitate to ask for these documents as part of their due diligence.

What Are the Benefits of Third-Party Inspections?

Engaging third-party inspectors can add an extra layer of assurance regarding the quality of the product. These independent evaluations can help identify potential risks and ensure that suppliers adhere to industry standards.

What Are the Quality Control and Certification Nuances for International B2B Buyers?

For international B2B buyers, particularly those in regions such as Africa, South America, the Middle East, and Europe, understanding the nuances of quality control and certification is crucial. Regulations can vary significantly between countries, and buyers should familiarize themselves with local requirements for pharmaceutical products.

How Can Buyers Navigate Regional Regulatory Differences?

Buyers should work with suppliers who are knowledgeable about the regulatory landscape in their target markets. This may include certifications like CE marking for products sold in Europe or compliance with local health authorities in African and South American nations.

What Challenges May Buyers Face in Ensuring Quality?

Challenges such as language barriers, differences in regulatory standards, and varying quality practices can complicate the supplier selection process. B2B buyers should prioritize suppliers with a proven track record in international markets and those who can demonstrate their commitment to quality assurance.

By understanding the manufacturing processes and quality assurance measures in place for ELIQUIS, B2B buyers can make informed decisions that ensure they are sourcing high-quality pharmaceutical products. This knowledge can significantly enhance their competitive advantage in the global marketplace.

Practical Sourcing Guide: A Step-by-Step Checklist for ‘who manufactures eliquis’

In this guide, we provide a practical checklist for B2B buyers interested in sourcing ELIQUIS (apixaban), a leading oral anticoagulant manufactured by Bristol Myers Squibb (BMS) and Pfizer. Understanding the manufacturing and sourcing process of ELIQUIS is crucial for ensuring quality, compliance, and effective supply chain management.

Step 1: Identify Your Procurement Needs

Before beginning the sourcing process, clarify your specific needs regarding ELIQUIS. Consider factors such as the quantity required, delivery timelines, and any regulatory requirements specific to your region. This clarity will guide your interactions with potential suppliers.

• Determine the volume you plan to purchase based on patient needs or market demand.
• Research local regulations regarding the importation and distribution of pharmaceuticals to ensure compliance.

Step 2: Research Approved Manufacturers

ELIQUIS is produced by Bristol Myers Squibb and Pfizer. Familiarize yourself with these companies and any authorized distributors in your region. Understanding the manufacturing process and quality control measures in place is critical for assessing reliability.

• Look for information on the manufacturers’ production facilities and quality assurance protocols.
• Check if the suppliers have the necessary certifications, such as Good Manufacturing Practices (GMP).

Step 3: Evaluate Supplier Certifications

Supplier certifications are a vital component of pharmaceutical sourcing. Ensure that potential suppliers have valid certifications that demonstrate compliance with international standards.

• Verify certifications like ISO 9001 or specific pharmaceutical certifications relevant to your region.
• Request documentation that confirms adherence to local and international health regulations.

Step 4: Assess Supply Chain Logistics

Understanding the logistics of how ELIQUIS will be delivered to your location is essential. Evaluate the supplier’s distribution capabilities and the reliability of their supply chain.

• Inquire about the supplier’s distribution network and their experience in handling pharmaceutical products.
• Consider the lead times for delivery and how they align with your operational needs.

Step 5: Request Pricing and Terms of Sale

Once you have identified potential suppliers, request pricing information and terms of sale. This step is essential to ensure that you receive competitive pricing and understand the total cost of procurement.

• Ask for detailed quotes that include shipping, handling, and any additional fees.
• Review payment terms and conditions to ensure they are favorable for your cash flow.

Step 6: Conduct Risk Assessment

Conducting a risk assessment is crucial when sourcing pharmaceuticals. Identify potential risks associated with sourcing ELIQUIS from different suppliers.

• Evaluate the financial stability of the suppliers and their history of compliance with regulations.
• Consider geopolitical factors that may affect supply stability, especially if sourcing from international suppliers.

Step 7: Establish a Communication Plan

Effective communication with your supplier is key to a successful procurement process. Establish a clear communication plan to address any concerns and ensure timely updates.

• Designate points of contact for both your organization and the supplier.
• Set regular check-ins to discuss order statuses, potential issues, and feedback on product quality.

By following this checklist, B2B buyers can navigate the complexities of sourcing ELIQUIS more effectively, ensuring compliance, quality, and reliability in their procurement processes.

Comprehensive Cost and Pricing Analysis for who manufactures eliquis Sourcing

What Are the Key Cost Components in Manufacturing ELIQUIS?

When analyzing the cost structure of ELIQUIS (apixaban), a leading oral anticoagulant, it is essential to understand the various components that contribute to its pricing. The primary cost components include:

• Materials: The raw materials for ELIQUIS consist of active pharmaceutical ingredients (APIs) and excipients. The cost of these materials can fluctuate based on global supply chain dynamics and sourcing locations. For example, APIs may be sourced from regions with established pharmaceutical manufacturing capabilities, impacting the overall cost.

• Labor: Labor costs encompass salaries, benefits, and training for personnel involved in the manufacturing process. Skilled labor is critical in maintaining quality and compliance with regulatory standards, which can increase costs, particularly in regions with higher wage expectations.

• Manufacturing Overhead: This includes costs related to facilities, utilities, and equipment maintenance. Efficient manufacturing processes can help mitigate these overhead costs, but initial investments in high-quality equipment and technology are often substantial.

• Tooling: The cost of specialized tooling and equipment necessary for the production of ELIQUIS can be significant. Custom tooling may be required for specific formulations or packaging, influencing the overall cost structure.

• Quality Control (QC): Rigorous quality assurance processes are essential in pharmaceutical manufacturing to meet regulatory requirements. These processes incur costs related to testing, validation, and compliance, which are critical for maintaining product integrity and market access.

• Logistics: Distribution costs, including transportation and warehousing, are vital in the overall pricing strategy. The global nature of pharmaceutical supply chains means that logistics can be affected by geopolitical factors, tariffs, and regional regulations.

• Margin: Manufacturers typically apply a margin to cover risks, innovations, and future investments. Understanding the expected margin is crucial for pricing negotiations, especially in international markets.

How Do Price Influencers Affect ELIQUIS Sourcing Decisions?

Several factors influence the pricing of ELIQUIS, particularly for international B2B buyers:

• Volume and Minimum Order Quantity (MOQ): Suppliers often provide better pricing for larger orders. Buyers should assess their purchasing needs to leverage economies of scale, which can significantly reduce unit costs.

• Specifications and Customization: Custom formulations or packaging can lead to higher costs. Buyers must balance the need for customization with cost considerations, ensuring that specifications align with market demands without inflating prices unnecessarily.

• Materials and Quality Certifications: The choice of materials and adherence to quality certifications (e.g., GMP, ISO) can impact pricing. Buyers should prioritize suppliers who meet stringent quality standards, as this can influence product reliability and market acceptance.

• Supplier Factors: Supplier reputation, reliability, and history of compliance with regulatory requirements are crucial. Establishing long-term relationships with reputable suppliers can often lead to better pricing and service.

• Incoterms: Understanding Incoterms is vital for managing shipping and logistics costs. Buyers should clarify responsibilities for shipping, insurance, and customs clearance to avoid unexpected costs.

What Tips Can Help International B2B Buyers Negotiate Better Prices?

Navigating the complexities of sourcing ELIQUIS requires strategic negotiation and cost-efficiency considerations. Here are some actionable tips for international B2B buyers:

• Engage in Open Negotiations: Establish transparent communication with suppliers regarding pricing structures and potential discounts for bulk orders. Leverage your position as a buyer to negotiate better terms.

• Consider Total Cost of Ownership (TCO): Evaluate the complete cost of procurement, including shipping, customs, and storage, rather than focusing solely on the purchase price. This approach helps in identifying the most cost-effective options.

• Stay Informed About Market Trends: Understanding global market trends and fluctuations in raw material prices can empower buyers to make informed decisions and time their purchases strategically.

• Utilize Local Representatives: For buyers from regions like Africa, South America, the Middle East, and Europe, having local representatives can facilitate better negotiations and understanding of regional compliance issues.

• Explore Alternative Suppliers: Diversifying the supplier base can enhance competition, leading to better pricing and service options. Consider sourcing from multiple regions to mitigate risks associated with geopolitical changes.

Disclaimer

The pricing insights provided herein are indicative and subject to change based on market conditions, supplier negotiations, and regional factors. It is advisable to conduct thorough market research and engage directly with suppliers for the most accurate and current pricing information.

Alternatives Analysis: Comparing who manufactures eliquis With Other Solutions

Exploring Alternatives to Eliquis Manufacturing

In the realm of anticoagulant medications, understanding the manufacturing sources and alternatives to Eliquis is crucial for B2B buyers in the pharmaceutical industry. Eliquis, manufactured by Bristol Myers Squibb and Pfizer, is a leading oral blood thinner used for conditions such as nonvalvular atrial fibrillation and the prevention of deep vein thrombosis (DVT). However, several alternative products and technologies exist that fulfill similar therapeutic needs. This analysis provides a comparative overview of Eliquis against other viable alternatives.

Comparison Aspect	Who Manufactures Eliquis	Alternative 1 Name: Xarelto	Alternative 2 Name: Pradaxa
Performance	Highly effective in reducing stroke risk and treating DVT/PE	Comparable efficacy in stroke prevention and DVT treatment	Effective in stroke prevention with a different mechanism of action
Cost	Generally higher due to brand recognition and patent protection	Competitive pricing; often lower than Eliquis	Similar price range to Eliquis, but varies by region
Ease of Implementation	Requires physician prescription and patient education	Simple prescription process; similar to Eliquis	Also requires prescription; education on usage is essential
Maintenance	Regular monitoring not typically required	Minimal monitoring needed; some renal function checks	Requires monitoring of renal function; can have dietary restrictions
Best Use Case	Ideal for patients with nonvalvular AFib and post-surgical DVT prevention	Suitable for a broad range of patients needing anticoagulation	Best for patients with specific renal function considerations

Detailed Breakdown of Alternatives

Xarelto (Rivaroxaban)
Xarelto is an alternative oral anticoagulant that, like Eliquis, is used for the prevention of stroke in patients with atrial fibrillation and for the treatment of DVT. One of its primary advantages is its competitive pricing, which can make it a more attractive option for healthcare providers and patients alike. The ease of prescribing and a minimal requirement for monitoring enhances its appeal. However, Xarelto may have limitations concerning certain patient populations, particularly those with compromised renal function, which can impact its safety and efficacy.

Pradaxa (Dabigatran)
Pradaxa operates through a different mechanism, providing an alternative option for anticoagulation therapy. It is especially noted for its efficacy in preventing strokes and has established itself as a trusted option in the market. However, it requires more stringent monitoring of renal function and has dietary restrictions that may complicate its use. Despite these challenges, Pradaxa remains a solid alternative for patients who may not respond well to other anticoagulants, providing flexibility in treatment plans.

Making the Right Choice as a B2B Buyer

When considering alternatives to Eliquis, B2B buyers must assess multiple factors, including performance, cost, and patient-specific needs. The decision should not only focus on price but also on the overall value provided to patients and healthcare systems. Understanding the unique characteristics of each alternative, including their mechanisms of action, monitoring requirements, and patient demographics, will enable buyers to make informed choices that align with their business objectives and patient care standards. Ultimately, the right solution will depend on a careful evaluation of these aspects in the context of market demands and patient requirements.

Essential Technical Properties and Trade Terminology for who manufactures eliquis

What Are the Key Technical Properties of ELIQUIS and Their Importance in Manufacturing?

Understanding the technical properties of ELIQUIS (apixaban) is crucial for B2B buyers engaged in pharmaceutical manufacturing or distribution. Here are some critical specifications and their relevance:

1. Active Pharmaceutical Ingredient (API) Specification
   The API for ELIQUIS is apixaban, which must meet stringent purity and potency criteria. High purity levels (typically over 99%) are essential to ensure efficacy and safety in patients. For manufacturers, compliance with these specifications is vital for regulatory approval and maintaining product integrity.

2. Dosage Formulation
   ELIQUIS is available in 2.5 mg and 5 mg oral tablets. The formulation must be consistent to ensure accurate dosing, which is critical for patient safety. For B2B buyers, understanding the formulation helps in predicting production costs and ensuring that the product meets therapeutic needs.

3. Stability Profile
   ELIQUIS has a defined stability profile, with a shelf life of 24 months when stored properly. This information is crucial for manufacturers and suppliers to establish inventory management practices and ensure that the product remains effective throughout its shelf life.

4. Bioavailability
   ELIQUIS has an oral bioavailability of approximately 50%, meaning that about half of the administered dose reaches systemic circulation. This property is essential for formulating effective dosing regimens and for understanding the drug’s therapeutic window. B2B buyers must consider this when evaluating product performance in clinical settings.

5. Packaging Requirements
   The packaging for ELIQUIS must be designed to protect it from moisture and light, ensuring product stability and integrity. Compliance with packaging regulations is necessary for market entry, making it a critical consideration for manufacturers and suppliers.

What Are Common Trade Terms in the ELIQUIS Manufacturing Industry?

Familiarity with industry jargon can streamline communication and negotiations between B2B buyers and manufacturers. Here are some essential trade terms:

1. OEM (Original Equipment Manufacturer)
   An OEM refers to a company that produces parts or equipment that may be marketed by another manufacturer. In the context of pharmaceuticals, OEMs may produce the active ingredients or formulations for ELIQUIS. Understanding this term helps buyers identify potential suppliers in the manufacturing chain.

2. MOQ (Minimum Order Quantity)
   MOQ specifies the smallest quantity of a product that a supplier is willing to sell. For ELIQUIS, understanding MOQ is essential for budgeting and inventory planning, as it affects initial order sizes and potential cost savings.

3. RFQ (Request for Quotation)
   An RFQ is a document issued by a buyer to solicit price quotes from suppliers for specific products or services. For B2B buyers in the pharmaceutical sector, submitting an RFQ for ELIQUIS can lead to competitive pricing and informed purchasing decisions.

4. Incoterms (International Commercial Terms)
   Incoterms are a set of international rules that define the responsibilities of buyers and sellers regarding the delivery of goods. Familiarity with these terms is essential for B2B buyers to understand shipping costs, risks, and responsibilities when importing ELIQUIS from various markets.

5. GMP (Good Manufacturing Practices)
   GMP refers to the guidelines and regulations that ensure products are consistently produced and controlled according to quality standards. Compliance with GMP is critical for the manufacturing of ELIQUIS to ensure product safety and efficacy, making it a vital consideration for B2B buyers when selecting suppliers.

Understanding these technical properties and trade terms can significantly enhance the decision-making process for B2B buyers involved in sourcing or manufacturing ELIQUIS, enabling better strategic planning and risk management.

Navigating Market Dynamics and Sourcing Trends in the who manufactures eliquis Sector

What Are the Current Market Dynamics and Key Trends in the ELIQUIS Manufacturing Sector?

The ELIQUIS manufacturing sector is primarily driven by the rising global prevalence of conditions such as atrial fibrillation (AFib), deep vein thrombosis (DVT), and pulmonary embolism (PE). As the demand for effective anticoagulants grows, so does the interest from international B2B buyers, particularly in emerging markets across Africa, South America, the Middle East, and Europe. Buyers are increasingly looking for reliable suppliers who can meet regulatory standards while also providing cost-effective solutions.

Current trends show a significant shift towards digitalization in sourcing practices. Advanced technologies, including artificial intelligence and blockchain, are being employed to enhance supply chain transparency and efficiency. This trend is particularly relevant for B2B buyers who prioritize traceability and quality assurance in pharmaceuticals. Furthermore, the increasing adoption of telemedicine and remote patient monitoring is reshaping how healthcare providers prescribe anticoagulants, influencing procurement strategies in the sector.

Another key dynamic is the competitive landscape of manufacturers. Major players like Bristol Myers Squibb and Pfizer are continuously innovating, not just in product development but also in patient support programs that assist in medication adherence. This focus on comprehensive patient care is essential for B2B buyers looking to partner with manufacturers who prioritize long-term relationships and added value.

How Are Sustainability and Ethical Sourcing Impacting the ELIQUIS Manufacturing Sector?

Sustainability is becoming a pivotal concern for B2B buyers in the pharmaceutical sector, including those interested in ELIQUIS manufacturing. The environmental impact of pharmaceutical production is under scrutiny, prompting manufacturers to adopt more sustainable practices. This includes reducing carbon footprints and minimizing waste through improved production processes.

Ethical sourcing is equally important, as buyers are increasingly seeking suppliers who demonstrate a commitment to social responsibility. This encompasses fair labor practices, responsible sourcing of raw materials, and adherence to stringent environmental regulations. Manufacturers who can provide certifications for sustainable practices or green materials are likely to gain a competitive edge in the market.

For B2B buyers, engaging with manufacturers that prioritize sustainability not only aligns with corporate social responsibility goals but also enhances brand reputation. As the global market shifts towards greener solutions, those who fail to adapt may find themselves at a disadvantage.

What Is the Brief Evolution and History of ELIQUIS in the B2B Context?

ELIQUIS, or apixaban, was developed through a collaboration between Bristol Myers Squibb and Pfizer, receiving FDA approval in 2012. Initially targeted at preventing stroke in patients with AFib, its applications have since expanded to include the treatment of DVT and PE, as well as the prevention of blood clots post-surgery.

The evolution of ELIQUIS reflects broader trends in the pharmaceutical industry, where the focus has shifted from merely developing effective medications to creating comprehensive patient solutions. This shift has significant implications for B2B buyers, who now seek not only high-quality products but also innovative support systems that enhance patient outcomes. As ELIQUIS continues to evolve, understanding its market trajectory will be crucial for international buyers looking to align with leading manufacturers in the anticoagulant space.

Frequently Asked Questions (FAQs) for B2B Buyers of who manufactures eliquis

1. How do I verify the manufacturer of ELIQUIS for my procurement needs?
   To verify the manufacturer of ELIQUIS, you should start by contacting Bristol Myers Squibb, the company that produces this medication. They can provide documentation and certifications that confirm their role as the manufacturer. Additionally, for international buyers, checking with local regulatory bodies or healthcare authorities can help ensure that the product meets local standards and is approved for distribution in your region.

2. What are the key considerations when sourcing ELIQUIS from international suppliers?
   When sourcing ELIQUIS internationally, consider factors such as the supplier’s credibility, compliance with local regulations, and their ability to provide necessary documentation (e.g., certificates of analysis). Additionally, assess their supply chain reliability, lead times, and experience in handling pharmaceutical products. Establishing clear communication and understanding payment terms is also crucial to avoid any misunderstandings.

3. What is the minimum order quantity (MOQ) for ELIQUIS?
   The minimum order quantity for ELIQUIS can vary significantly between suppliers and regions. Typically, larger pharmaceutical manufacturers may have higher MOQs due to production costs and regulatory requirements. It’s advisable to discuss your specific needs with potential suppliers to negotiate favorable terms, especially if you are a smaller buyer or entering a new market.

4. How can I ensure the quality of ELIQUIS when sourcing it internationally?
   To ensure the quality of ELIQUIS, request certificates of good manufacturing practices (GMP) from the supplier. Conduct regular quality assurance checks and consider third-party testing if necessary. Establishing a quality control agreement that outlines the standards and testing methods can also help maintain product integrity throughout the supply chain.

5. What payment terms should I expect when purchasing ELIQUIS?
   Payment terms for ELIQUIS can vary widely depending on the supplier and your negotiation. Common arrangements include upfront payments, letters of credit, or net payment terms (e.g., net 30 or 60 days). Always ensure that payment terms are clearly outlined in the contract to protect both parties and facilitate smooth transactions.

6. How do I handle logistics and shipping for ELIQUIS?
   Handling logistics for ELIQUIS requires careful planning. Ensure that your supplier is experienced in pharmaceutical logistics, including temperature control if necessary. Discuss shipping options, timelines, and customs clearance processes in advance. Collaborating with a logistics partner familiar with international regulations can help ensure timely and compliant delivery.

7. What regulations should I be aware of when importing ELIQUIS into my country?
   Importing ELIQUIS involves navigating various regulations, including drug import licenses, customs regulations, and adherence to local health authority standards. Each country has specific requirements, so it’s crucial to consult local regulatory agencies or legal experts to ensure compliance and avoid potential fines or product seizures.

8. Can I customize ELIQUIS packaging for my market?
   Customization of ELIQUIS packaging is generally possible, but it requires coordination with the manufacturer and compliance with local regulations. Discuss your branding and packaging needs with the supplier to understand the feasibility and associated costs. Additionally, ensure that any changes meet regulatory standards for labeling and safety information in your market.

Important Disclaimer & Terms of Use

Strategic Sourcing Conclusion and Outlook for who manufactures eliquis

In the complex landscape of pharmaceutical sourcing, understanding the manufacturers of ELIQUIS (apixaban) is crucial for international B2B buyers. Bristol Myers Squibb (BMS) is the primary manufacturer of this leading oral anticoagulant, known for its efficacy in reducing the risk of stroke in patients with nonvalvular atrial fibrillation and treating deep vein thrombosis (DVT). Leveraging strategic sourcing practices can enhance procurement efficiency, ensuring that businesses not only secure reliable supply chains but also optimize costs associated with high-demand medications like ELIQUIS.

For buyers in regions such as Africa, South America, the Middle East, and Europe, tapping into BMS’s resources and patient assistance programs can facilitate smoother access to this essential drug. Furthermore, understanding the regulatory landscape and market dynamics in these regions can empower companies to make informed sourcing decisions.

Looking ahead, the global demand for anticoagulants is expected to rise, creating opportunities for strategic partnerships and collaboration. B2B buyers are encouraged to engage actively with manufacturers and distributors to navigate this evolving market effectively. By prioritizing strategic sourcing and fostering strong supplier relationships, businesses can ensure they remain competitive and responsive to the needs of healthcare providers and patients alike.